XML 50 R38.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenue Recognition (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended |
--- | --- | --- | ---
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | Dec. 31, 2017
Disaggregation of Revenue [Line Items] |  |  |  |  |
Contract with Customer, Liability | $ 24.2 |  | $ 24.2 |  | $ 33.6
Percentage of net sales | 100.00% | 100.00% | 100.00% | 100.00% |
Sales Revenue, Net [Member] | Product Concentration Risk [Member] | High-Value Components [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percentage of net sales | 43.00% | 41.00% | 42.00% | 42.00% |
Sales Revenue, Net [Member] | Product Concentration Risk [Member] | Standard Packaging [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percentage of net sales | 31.00% | 34.00% | 32.00% | 34.00% |
Sales Revenue, Net [Member] | Product Concentration Risk [Member] | Delivery Devices [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percentage of net sales | 3.00% | 4.00% | 4.00% | 4.00% |
Sales Revenue, Net [Member] | Product Concentration Risk [Member] | Contract-Manufactured Products [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percentage of net sales | 23.00% | 21.00% | 22.00% | 20.00% |
Biologics [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percentage of net sales | 21.00% | 23.00% | 22.00% | 23.00% |
Generics [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percentage of net sales | 21.00% | 20.00% | 21.00% | 20.00% |
Pharma Customers [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percentage of net sales | 35.00% | 36.00% | 35.00% | 37.00% |
Contract-Manufactured Products [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percentage of net sales | 23.00% | 21.00% | 22.00% | 20.00% |
Americas [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percentage of net sales | 48.00% | 52.00% | 47.00% | 52.00% |
Europe, Middle East, Africa [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percentage of net sales | 44.00% | 41.00% | 45.00% | 41.00% |
Asia Pacific [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percentage of net sales | 8.00% | 7.00% | 8.00% | 7.00% |

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6351-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13531-108611 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6404-108592 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13537-108611 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=wst_HighValueComponentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=wst_StandardPackagingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=wst_DeliveryDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=wst_ContractManufacturedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=wst_BiologicsCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=wst_GenericsCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=wst_PharmaCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=wst_ContractManufacturedCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_AmericasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_EMEAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_AsiaPacificMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |